Small Molecules

all catalysts(0)

nothing on the calendar yet

News(10)

• Foghorn cuts 40% of workforce
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 2d ago
• David Sinclair's latest salvo aims to stall aging with a pill
  BOSTON — Scientists say they’ve discovered small molecules that can reprogram cells to a younger state, raising the possibility that a simple pill could one day broadly combat aging. Christopher Pe…
  endpoints · 2d ago
• Webinar: From Facility to Delivery: Solving the Complex Science of ADC Linker-Payload Synthesis
  In this webinar, experts from SK pharmteco’s European and North American sites share practical experience addressing these challenges across the linker-payload development lifecycle—from facility a…
  biospace · 5d ago
• ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
  When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
  fiercebiotech · 6d ago
• Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
  The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.
  biospace · 10d ago
• Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
  Roche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.
  fiercebiotech · 10d ago
• Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo
  Orbis Medicines will help Novo create macrocycles — those ring-shaped molecules that marry the best of antibodies and small molecules — for cardiometabolic diseases as part of an up to $1.4 billion…
  endpoints · 17d ago
• Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
  Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with oral macrocycle drug start-up Orbis Medicines.
  fiercebiotech · 18d ago
• Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
  Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.
  fiercebiotech · 18d ago
• Cyclic peptides open new drug frontiers, if manufacturing can keep up
  With oral cyclic peptides offering small molecule convenience and antibody‑like selectivity, the modality is gaining momentum. But bioavailability below 1%, minimal PK data and fragile synthesis st…
  biospace · 20d ago